(Q33867243)

English

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection (English)

1 reference

Europe PubMed Central

29 July 2017

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Chun-Yen Lin

1

1 reference

Europe PubMed Central

29 July 2017

Ji-Yih Chen

2

1 reference

Europe PubMed Central

29 July 2017

Tsung-Nan Lin

3

1 reference

Europe PubMed Central

29 July 2017

Wen-Juei Jeng

4

1 reference

Europe PubMed Central

29 July 2017

Chien-Hao Huang

5

1 reference

Europe PubMed Central

29 July 2017

Chang-Wen Huang

6

1 reference

Europe PubMed Central

29 July 2017

Su-Wei Chang

7

1 reference

Europe PubMed Central

29 July 2017

I-Shyan Sheen

8

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

30 March 2011

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

6

1 reference

Europe PubMed Central

29 July 2017

3

1 reference

Europe PubMed Central

29 July 2017

e18322

1 reference

Europe PubMed Central

29 July 2017

copyright license

Creative Commons Attribution 4.0 International

30 March 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Hepatitis C pharmacogenetics: state of the art in 2010.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

IL28B and the control of hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

The recent breakthroughs in the understanding of host genomics in hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Treatment of chronic hepatitis C in Asia: when East meets West.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

5 July 2018

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Genomics: Hepatitis C virus gets personal

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0018322

21 January 2018

Interferon-lambda serum levels in hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

29 October 2018

Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

29 October 2018

Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

29 October 2018

Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3068186

29 October 2018

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/21479134

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0018322

1 reference

Europe PubMed Central

29 July 2017

2011PLoSO...618322L

0 references

release_x5wf72sohfc7jeldvgqpogg3gy

1 reference

https://api.fatcat.wiki/v0/release/x5wf72sohfc7jeldvgqpogg3gy

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33867243&oldid=1987985520"